Amgen (AMGN) PT Raised to $300 at Oppenheimer on 'Incremental Conviction in Cardiometabolic Pipeline'
Tweet Send to a Friend
Oppenheimer analyst Jay Olson raised the price target on Amgen (NASDAQ: AMGN) to $300.00 (from $290.00) while maintaining an Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
